ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

reproxalap

Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.

Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.

Drug pageReproxalap: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 4, 201721 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aldeyra Therapeuticsits history only200 open or runningphase 3since Apr 4, 2017Dec 14, 2016none ahead
Aldena Therapeutics11 open or runningphase 2since Jan 22, 2025Jan 22, 2025Nov 2026phase 2 · NCT06826196

Also a collaborator on its studies: ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aldena Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named reproxalapINNProposed as its International Nonproprietary Name in WHO's List 119
  2. Jan 22, 2025First study: phase 2 study in Alopecia AreataFirst studyNCT06826196 · 9 enrolled · United States, Canada

Ahead

  1. Nov 2026Primary completion: phase 2 study in Alopecia AreataNCT06826196

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Aldena Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06826196Alopecia Areata · United States, Canada2Active, not recruitingNov 20269

How it is read

Names in the registry

  • “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
  • “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
  • “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
  • “ALD-102 Solution”, 1 entry
  • “Reproxalap ophthalmic solution (0.25%)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.